Discussion | This study of 353 outpatients demonstrates that most patients who miss a dermatology appointment continue to use dermatology services. Although dermatology is primarily an outpatient specialty, 36.6% of subsequent dermatology use came from hospitalizations and emergency department visits.
Patient nonattendance occurs when patients miss appointments without notifying their health care professionals in advance. In dermatology, nonattendance rates range from 7.8% to 31.0% of scheduled appointments. 1 The consequences of nonattendance range from compromised care to wasted appointment slots, decreased efficiency, and diluted residency training. 2 We seek to define the effect of nonattendance on subsequent use of health care resources and health care spending in dermatology.
Methods | The study included patients within the Partners
Healthcare System who were seen at the dermatology office of Brigham and Women's Hospital in Boston or in an associated suburban satellite clinic and who missed at least 1 dermatology appointment from February 1, 2009, through July 30, 2010. Of the 2289 patients who met these criteria, 250 randomly selected urban patients and all 237 suburban patients were included. Patients with a primary care physician outside Partners Healthcare System (128 patients) and those younger than 18 years at the time of the appointment (6 patients) were excluded, leaving 353 patients. This retrospective study was approved by the institutional review board of Partners Healthcare System, who waived the requirement for a patient to consent to receive treatment. Patient data were deidentified.
We reviewed each patient's medical record to collect demographics, medical history, and dermatology-specific health care use in the 3 years after the missed appointment (final date of follow-up, July 30, 2013). We performed cost calculations using 2009-2010 figures from the Center for Medicare & Medicaid Services 3 and 2011-2013 data from the Agency for Healthcare Research and Quality. [4] [5] [6] The cost of a missed appointment, including a physician's time and unused space, was defined as 50% of the cost of an attended appointment. Sensitivity analysis used to test costs from 25% to 75% of an attended appointment did not affect our conclusions.
The composite cost measure reflects missed and attended outpatient appointments, dermatology-related emergency department visits and inpatient stays, and biopsies. Surgical procedures, imaging, prescriptions, and other costs related to treatment were not included. Patients with high rates of use were defined as the top 10% of patients in relation to the cost measure. Changing this definition to those with values ranging from 5% to 15% did not affect the analysis.
Data were analyzed from February 1, 2009, through July 30, 2010. We performed a univariable analysis of all potential predictive variables and a multivariable analysis on all variables with P < .15.
Results | Overall, 47 of 353 patients (13.3%) failed to attend a dermatology appointment. Most of these patients (245 [69.4%]) had subsequent use of dermatology services after nonattendance. Costs were concentrated in a small proportion of these patients, with the top 10% (n=35) responsible for 60.9% of costs (Figure) . The overall dermatologic spending was divided among inpatient costs (31.6%), emergency department costs (5.0%), attended outpatient appointments (51.0%), missed outpatient appointments (7.0%), and biopsies (4.4%). A multivariable analysis identified that missing a return visit (adjusted odds ratio, 3.69; 95% CI, 1.27-13.46) and having a history of nonmelanoma skin cancer (adjusted odds ratio, 3.97; 95% CI, 1.53-10.31) were associated with high rates of use (Table) . Abbreviations: NMSC, non-melanoma skin cancer; OR, odds ratio. a Odds ratios from unadjusted and fully adjusted logistic regression models were used to describe associations between patient characteristics and high rates of use after nonattendance. b Variable was forced in; otherwise, unadjusted P < .15 required for inclusion in this Table. 
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